Detalhe da pesquisa
1.
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
Cell
; 162(1): 146-59, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26140595
2.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197815
3.
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Cell
; 150(6): 1107-20, 2012 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22980975
4.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870973
5.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med
; 389(22): 2063-2075, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861218
6.
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.
Br J Cancer
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38750115
7.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet
; 401(10378): 733-746, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36764316
8.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
N Engl J Med
; 384(25): 2371-2381, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096690
9.
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Future Oncol
; 20(3): 113-120, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010044
10.
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(10): 944-957, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877583
11.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846060
12.
[Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]. / Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms.
Pneumologie
; 77(10): 671-813, 2023 Oct.
Artigo
em Alemão
| MEDLINE | ID: mdl-37884003
13.
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Lancet Oncol
; 23(10): 1261-1273, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108661
14.
Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.
BMC Health Serv Res
; 22(1): 543, 2022 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459202
15.
Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung.
Histopathology
; 78(4): 578-585, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946634
16.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol
; 17(7): 763-773, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150799
17.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838015
18.
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
BMC Cancer
; 20(1): 408, 2020 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32397977
19.
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
Mod Pathol
; 32(5): 627-638, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30459450
20.
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
J Pathol
; 246(1): 67-76, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29885057